A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2016

At a glance

  • Drugs Cavosonstat (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms SNO2
  • Sponsors N30 Pharma; Nivalis Therapeutics
  • Most Recent Events

    • 17 Mar 2015 Secondary outcome of PK has been moved to primary outcomes; so study focus changed to AR plus PK as reported by ClinicalTrials.gov
    • 03 Feb 2015 Status changed from active, no longer recruiting to completed as reported by N30 Pharmaceuticals media release.
    • 11 Jan 2015 Treatment table changed. A treatment arm with 500 mg N91115 for 14 days has been added to the treatment table as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top